KEGG   DRUG: Adalimumab
Entry
D02597                      Drug                                   

Name
Adalimumab (USAN/INN);
Adalimumab (genetical recombination) (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN);
Humira (TN)
Product
Class
Other
 DG01936  TNF inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AB04
Product: D02597<JP/US>
Efficacy
Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody
  Disease
Rheumatoid arthritis [DS:H00630]
Juvenile idiopathic arthritis [DS:H01672]
Psoriatic arthritis [DS:H01507]
Ankylosing spondylitis [DS:H01674]
Adult Crohn's disease [DS:H00286]
Pediatric Crohn's disease [DS:H00286]
Ulcerative colitis [DS:H01466]
Plaque psoriasis [DS:H01656]
Hidradenitis suppurativa [DS:H00681]
Comment
Monoclonal antibody
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04210  Apoptosis
hsa04350  TGF-beta signaling pathway
hsa04380  Osteoclast differentiation
hsa04612  Antigen processing and presentation
hsa04650  Natural killer cell mediated cytotoxicity
hsa05321  Inflammatory bowel disease (IBD)
hsa05323  Rheumatoid arthritis
Interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
     L04AB04 Adalimumab
      D02597  Adalimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunosuppressants
   Tumor Necrosis Factor (TNF) Blockers
    Adalimumab
     D02597  Adalimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D02597  Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D02597  Adalimumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02597
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02597
Other DBs
CAS: 331731-18-1
PubChem: 47205810
DrugBank: DB00051
NIKKAJI: J2.104.916F
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system